替诺福韦-阿拉芬酰胺
恩替卡韦
乙型肝炎表面抗原
医学
内科学
胃肠病学
HBeAg
肾功能
乙型肝炎病毒
乙型肝炎
慢性肝炎
临床终点
肌酐
β-2微球蛋白
拉米夫定
显著性差异
代理终结点
病毒学
不利影响
尿
作者
Jungnam Lee,Young‐Joo Jin
摘要
Entecavir (ETV) and tenofovir alafenamide (TAF) are two first-line nucleos(t)ide analogs used for the treatment of chronic hepatitis B (CHB), each offering potent antiviral activity and a high barrier to resistance. We aimed to directly compare the effects of ETV and TAF on the quantitative reduction of hepatitis B surface antigen (HBsAg) levels in CHB patients. We screened 1342 consecutive CHB patients treated with ETV or TAF at our center between January 2007 and December 2021. In total, 493 patients were included in the final analysis (ETV, n = 169; TAF, n = 324). The primary endpoint was the difference in quantitative HBsAg reduction between the two groups at 12 and 24 months. Secondary endpoints included changes in the estimated glomerular filtration rate (eGFR), phosphorus, and low-density lipoprotein (LDL)-cholesterol levels. Although the absolute median HBsAg reduction was not significantly different between the TAF and ETV groups (p > 0.05), more patients in the TAF group achieved > 10% quantitative HBsAg decline at 12 months (63.0% vs. 55.8%, p = 0.009) and 24 months (81.7% vs. 65.1%, p < 0.001). The TAF group demonstrated a stable median eGFR (mL/min/1.73 m²) change compared to the ETV group (0.0 vs. -6.0, p = 0.003) at 24 months. The TAF group showed better preservation of serum phosphorus levels at 24 months (p = 0.003). The changes in LDL-cholesterol levels were not significantly different between the two groups. In CHB patients, TAF showed a significantly higher proportion of quantitative HBsAg reduction and a superior renal safety profile than ETV, without significant differences in LDL-cholesterol changes.
科研通智能强力驱动
Strongly Powered by AbleSci AI